Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Lung Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Metastatic Urothelial Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Injections 12pembrolizumab 11Nivolumab 9Paclitaxel 8senaparib 7Docetaxel 7Cisplatin 6Capecitabine 6Gemcitabine 5toripalimab 4tislelizumab 4atezolizumab 4Ipilimumab 4Carboplatin 4Bevacizumab 4sintilimab 3Rifampin 3Oxaliplatin 3Itraconazole 3130-nm albumin-bound paclitaxel 3zimberelimab 2pertuzumab 2osimertinib 2ontuxizumab 2navoximod 2magrolimab 2fluzoparib 2famitinib 2durvalumab 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor × zimberelimab × Clear all
NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

Gilead Sciences

Phase 1 Active not recruiting
182 enrolled
Other solid neoplasm

Solid Tumor

NCT05909436 2023-06-18

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1/2 Recruiting
107 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡